Work.

End-to-end AI stack combining a custom UI layer (Knowledge Graph, ChatAlphaMeld, Bioinformatics, Literature Analysis, AlphaClinMeld) with 12 ML models — including NER, RE, evidence scoring, digital-twin CT predictors and landscape assessment — running on PostgreSQL + Neo4j and self-hosted GPT/Claude custom APIs.

Guided drug-discovery hypothesis-generation platform built on the AlphaMeld Knowledge Graph. Supports four starting points — disease-first, target-first, indication expansion, and combination therapy — through a step-by-step workflow (project → config → exploration → agent scoring → ranking → hypotheses). A project-aware Discovery Copilot accompanies every step. Multi-tenant SaaS with SSO, RBAC, and audit logging.

Two agentic workflow engines fine-tuned on biomedical tasks; outperformed GPT-4o, GPT-4o-mini, and o3-mini variants; delivered richer step-by-step rationales critical for complex clinical questions.

End-to-end AI stack combining Knowledge Graph, Clinical Trial Prediction, Literature Analysis, Patient Digital Twin, TPP, TOP with 12 ML models running on PostgreSQL + Neo4j and self-hosted GPT/Claude custom APIs.

Clinical-trial–centric SaaS module on AlphaMeld® graph analytics; benchmarks pipeline assets and quantifies comparative risk. Adopted by two BD teams within six months, standardizing evidence-based indication-prioritization across 200 active programs.

Conditional variational auto-encoder (CVAE) pipeline that synthesizes patient-level digital twins for Phase II Type 2 Diabetes trials. Generated matched placebo trajectories and predicted drug-response curves — proving feasibility of in-silico arms for protocol optimization and hypothesis testing.

Investment research platform for small/mid-cap NASDAQ biotechs where a single trial readout can move the stock 50%+. Syncs clinical-trial data (ClinicalTrials.gov, Clinical Navigator) with live stock and financials (Alpha Vantage), then runs LLM catalyst discovery and streaming AI predictions for upcoming readouts, PDUFA dates, partnerships, and conference events. Includes bulk catalyst briefings and an interactive research chat.

Secure, role-based platform for pharma/biotech regulatory affairs teams to search, analyze, compare, and manage global drug and biologic approvals. Covers pharmaceuticals, biologics, biosimilars, and generics across 12+ regulators. Combines role-based dashboards, pathway and classification guides, dossier preparation support, a centralized guidelines library, Q&A with expert responses, and AI-assisted document analysis (GPT-4, Claude).

Fully agent-orchestrated, multi-step LLM process. Input parameters, run a series of LLM processes to extract information from the web, compile, and store in a dashboard or export to Excel.

End-to-end booking and scheduling platform — custom-built to client specification with real-time availability, notifications, and management dashboard.

AI assistant that mines global regulatory updates and auto-drafts submission dossiers; established a new non-pharma revenue channel.